traffic information | weather | web feeds| mobile
Silicon Valley
Part of the Bay Area News Group
  • Site
  • Web Search by YAHOO!
Home
News
Venture Capital
Personal Tech
The Valley
Hot Topics
Phones/Mobile
Social Networks
Green Energy
Security
Companies
Apple
Google
Facebook
Cisco Systems
Intel
Hewlett-Packard
Oracle
Yahoo
eBay
Gilead Sciences
Adobe Systems
Intuit
Netflix
Electronic Arts
Tesla Motors
Twitter
Zynga
SunPower
Solyndra
Kleiner Perkins
People
Steve Jobs
Larry Ellison
Eric Schmidt
Mark Zuckerberg
Carol Bartz
John Doerr
John Chambers
Paul Otellini
Vinod Khosla
Mark Andreessen
Ron Conway
Biz Stone
Elon Musk
Larry Page
Sergey Brin
Ann Livermore
Marissa Mayer
Sheryl Sandberg
T.J. Rodgers
Mark Hurd
columnists
gmsv
Special Reports
Venture Capital Survey
Salary Survey
Silicon Valley 150
Services
RSS Feeds
Mobile Edition
Widgets
Contact Us
Jobs
Advertising
Archives
Go to MercuryNews.com
Silicon Valley 150
Markets
Stocks
Mutual Funds & ETF's
Sectors
Rates
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
NYSE COMPOSITE INDX
Gold
WTI Crude Oil
Greek Debt Weighs Markets Down To Lower Open
By: MarketMinute.com Market Updates
Posted on January 30, 2012 at 09:40 AM EST

Greece continued struggling with its debt problems to weigh the markets down to a shapely lower open with the Dow plunging 108 points to 12,55. Nasdaq tumbled 28 points to 2787.

On the upside

Gores Group will take Pep Boys - Manny, Moe & Jack (NYSE: PBY) private for approximately $791 million in cash.


ABB will pay approximately $3.9 billion in cash to acquire Thomas & Betts (NYSE: TNB).

The Food and Drug Administration approved Amylin Pharmaceuticals' (Nasdaq: AMLN) diabetes treatment Bydureon on Friday.


On the downside


Cell Therapeutics (Nasdaq: CTIC) withdrew the New Drug Application for its non-Hodgkin's lymphoma treatment Pixuvri.


Gannett (NYSE: GCI) reported sharply lower fourth quarter earnings as revenue dropped.

StemCells (Nasdaq: STEM) reported upbeat preclinical data that its purified human neural stem cells preserved vision in an animal model of retinal disease but the stock price fell.

In the broad market, declining issues outpaced advancers by a margin of more than 5 to 1 on the NYSE and by nearly 4 to 1 on Nasdaq. The Russell 2000 which tracks small cap stocks dropped 9 points to 789.

Related Stocks:
Amylin Pharmaceuticals, Inc. CELL THERAPEUTICS Dow Jones Industrial Average (EOD) Gannett Co., Inc. NASDAQ 100 NASDAQ Composite Pep Boys-Manny Moe & Jack Russell 1000 Index Russell 2000 Russell 3000 Index STEMCELLS Standard & Poors 500 Thomas & Betts Corp.
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Mortgage Rates, CD Rates & Home Equity Rates provided by Banks.com
Press Release Service provided by PRConnect.
Fundamental data supplied by Morningstar
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here
  • Terms of Use & Privacy Statement
  • Copyright ©
  • About our Ads
  • Find San Jose jobs
  • About MediaNews Group
  • RSS
  • About Bay Area News Group
  • Site Map

Media News Group